254 related articles for article (PubMed ID: 32552577)
41. CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing.
García-Roca P; Medeiros M; Reyes H; Rodríguez-Espino BA; Alberú J; Ortiz L; Vásquez-Perdomo M; Elizondo G; Morales-Buenrostro LE; Mancilla Urrea E; Castañeda-Hernández G
Arch Med Res; 2012 May; 43(4):283-7. PubMed ID: 22704849
[TBL] [Abstract][Full Text] [Related]
42. CYP3A5 Expressor Genotype of the Transplanted Kidney Increases the Risk of Preterm Graft Loss and Acute Rejection.
Warzyszyńska K; Zawistowski M; Karpeta E; Jałbrzykowska A; Kosieradzki M
Nephron; 2023; 147(7):441-450. PubMed ID: 36630936
[TBL] [Abstract][Full Text] [Related]
43. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
[TBL] [Abstract][Full Text] [Related]
44. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.
Elens L; Capron A; van Schaik RH; De Meyer M; De Pauw L; Eddour DC; Latinne D; Wallemacq P; Mourad M; Haufroid V
Ther Drug Monit; 2013 Oct; 35(5):608-16. PubMed ID: 24052064
[TBL] [Abstract][Full Text] [Related]
45. Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients.
Miura M; Satoh S; Kagaya H; Saito M; Numakura K; Tsuchiya N; Habuchi T
Pharmacogenomics; 2011 Jul; 12(7):977-84. PubMed ID: 21635144
[TBL] [Abstract][Full Text] [Related]
46. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation.
Uesugi M; Kikuchi M; Shinke H; Omura T; Yonezawa A; Matsubara K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
Pharmacogenet Genomics; 2014 Jul; 24(7):356-66. PubMed ID: 24911663
[TBL] [Abstract][Full Text] [Related]
47. CYP3A5 genotype had no impact on intrapatient variability of tacrolimus clearance in renal transplant recipients.
Spierings N; Holt DW; MacPhee IA
Ther Drug Monit; 2013 Jun; 35(3):328-31. PubMed ID: 23666583
[TBL] [Abstract][Full Text] [Related]
48. Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus.
Chen JS; Li LS; Cheng DR; Ji SM; Sun QQ; Cheng Z; Wen JQ; Sha GZ; Liu ZH
Transplant Proc; 2009 Jun; 41(5):1557-61. PubMed ID: 19545678
[TBL] [Abstract][Full Text] [Related]
49. Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients.
Gómez-Bravo MA; Salcedo M; Fondevila C; Suarez F; Castellote J; Rufian S; Pons JA; Alamo JM; Millán O; Brunet M
J Clin Pharmacol; 2013 Nov; 53(11):1146-54. PubMed ID: 23900887
[TBL] [Abstract][Full Text] [Related]
50. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation.
Bouamar R; Hesselink DA; van Schaik RH; Weimar W; Macphee IA; de Fijter JW; van Gelder T
Ther Drug Monit; 2011 Apr; 33(2):178-84. PubMed ID: 21383650
[TBL] [Abstract][Full Text] [Related]
51. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.
Monchaud C; de Winter BC; Knoop C; Estenne M; Reynaud-Gaubert M; Pison C; Stern M; Kessler R; Guillemain R; Marquet P; Rousseau A
Clin Pharmacokinet; 2012 Mar; 51(3):175-86. PubMed ID: 22339449
[TBL] [Abstract][Full Text] [Related]
52. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients.
Gijsen V; Mital S; van Schaik RH; Soldin OP; Soldin SJ; van der Heiden IP; Nulman I; Koren G; de Wildt SN
J Heart Lung Transplant; 2011 Dec; 30(12):1352-9. PubMed ID: 21930396
[TBL] [Abstract][Full Text] [Related]
53. Conversion from Twice-Daily Prograf
Yau WP; Loh CW; Vathsala A
Eur J Drug Metab Pharmacokinet; 2019 Aug; 44(4):481-492. PubMed ID: 30471066
[TBL] [Abstract][Full Text] [Related]
54. Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation.
Argudo A; González de Aledo JM; Alía P; Ramírez P; Serrano T; Fabregat J; Castellote J
Transplant Proc; 2015 Oct; 47(8):2388-92. PubMed ID: 26518936
[TBL] [Abstract][Full Text] [Related]
55. [Effect of CYP3A4*18B, CYP3A5*3 gene polymorphism on dosage and concentration of tacrolimus in renal transplant patients].
Zhu L; Song HT; Wang QH; Wu WZ; Yang SL; Tan JM
Yao Xue Xue Bao; 2012 Jul; 47(7):878-83. PubMed ID: 22993851
[TBL] [Abstract][Full Text] [Related]
56. Switching Immunosuppression From Cyclosporine to Tacrolimus in Kidney Transplant Recipients Based on CYP3A5 Genotyping.
Wang X; Yang Y; Liu Z; Xiao C; Gao L; Zhang W; Zhang W; Wang Z
Ther Drug Monit; 2019 Feb; 41(1):97-101. PubMed ID: 30520827
[TBL] [Abstract][Full Text] [Related]
57. Effect of CYP3A5*1 expression on tacrolimus required dose after liver transplantation: A systematic review and meta-analysis.
Hendijani F; Azarpira N; Kaviani M
Clin Transplant; 2018 Aug; 32(8):e13306. PubMed ID: 29855074
[TBL] [Abstract][Full Text] [Related]
58. Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients.
Satoh S; Kagaya H; Saito M; Inoue T; Miura M; Inoue K; Numakura K; Tsuchiya N; Tada H; Suzuki T; Habuchi T
Br J Clin Pharmacol; 2008 Aug; 66(2):207-14. PubMed ID: 18429967
[TBL] [Abstract][Full Text] [Related]
59. Prograf produces more benefits for CYP3A5 low expression patients in early stage after kidney transplantation.
Fan B; Qiu K; Jiang Y; Hu X; Yin H; Wang W; Ren L; Liu H; Wang W; Zhang X
Biomed Pharmacother; 2017 Apr; 88():738-744. PubMed ID: 28157649
[TBL] [Abstract][Full Text] [Related]
60. Unraveling the Genomic Architecture of the CYP3A Locus and ADME Genes for Personalized Tacrolimus Dosing.
Yoon JG; Song SH; Choi S; Oh J; Jang IJ; Kim YJ; Moon S; Kim BJ; Cho Y; Kim HK; Min S; Ha J; Shin HS; Yang CW; Yoon HE; Yang J; Lee MG; Park JB; Kim MS;
Transplantation; 2021 Oct; 105(10):2213-2225. PubMed ID: 33654003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]